New insulin and parenteral facility
Torrent Pharmaceuticals and Novo Nordisk India opened a new greenfield insulin and parenteral facility at the former’s parenteral facility in Indrad, Gujarat, India, in December 2017.
The new facility was built as part of an agreement signed by Torrent Pharma with Novo Nordisk India in August 2005 to dedicate a part of its Indrad parenteral facility to carry out works related to insulin formulating and packaging.
The plant has been manufacturing insulin for Novo Nordisk products for more than 15 years. The new greenfield site will enable Novo Nordisk to meet the increasing demand for insulin products in India.
According to the International Diabetes Federation 8th Atlas, India has approximately 72.9 million people with diabetes, which is expected rise up to approximately 134.3 million by 2045. The new plant will enable Novo Nordisk to provide affordable and quality medication to address the growing challenge.
The new facility incorporates state-of-art technology from the formulation of insulin to the packaging of insulin formulations. It has a systematic and single directional movement for both the people and material in the entire pharmaceutical area.
Provisions have been made for utilities such as WFI and Clean Steam Generator with capacities of 3m³/h and 800kg/h respectively. The civil structure of the facility was built using prefabricated modular partitions.
Designed to comply with cGMP and EU GMP standards, the greenfield facility will produce insulin vials, lyophilised products and liquid ampoules/vials.
The existing Indrad parenteral facility has a capacity of 12.5 million insulin vials, 14.4 million vials of lyopholiser and 15 million ampoules. The new facility will increase the capacity to 15 million insulin vials and 30 million ampoules.
The plant’s initial capacity will be enough to meet the market demand for a period of five years, following which a second line is planned to be added. The plant’s capacity will be increased to 300 million insulin vials with the addition of the second line.
The Indrad facility is built on a 194,000m² site, with a 46,000m² built-up area for formulations operations and 14,000m² for active pharmaceutical ingredients (API) operations.
Set up in 1989, the plant manufactures finished products in the oral, injectable and freeze-dried sterile injections form. It is compliant with various regulatory norms such as USFDA, WHO, cGMP and MHRA, and is also ISO-certified.
Based in Denmark, Novo Nordisk is a leading global healthcare company that has been involved in diabetes care for more than 90 years. It markets various treatments for obesity, haemophilia, growth disorders and other serious chronic diseases.
Novo Nordisk has more than 41,700 employees in 77 countries and has a global footprint in 165 countries. It partnered with Torrent Pharma in 1992 to manufacture insulin vials.
Apart from the Indrad plant, Torrent Pharma operates formulation and bulk drugs manufacturing plants at Baddi, Sikkim, Dahej, Pithampur and Vizag. The plants are approved by regulatory bodies of the US, UK, Brazil, Germany, Australia and South Africa.
Torrent also has a fully equipped research centre with approximately 900 scientists.
Lonza has developed a new biomanufacturing complex at its biopark in Visp, Switzerland. Located in Valais, the biomanufacturing complex features…
Janssen Sciences Ireland has expanded its biomedicines manufacturing facility in Barnahely, Ringaskiddy in County Cork, Ireland, with the addition of…
US-based healthcare company Grail is building a state-of-the-art laboratory facility in the Research Triangle Park (RTP), North Carolina. The facility will…
In July 2019, the UK-based Wasdell Group (Wasdell) opened a state-of-the-art pharmaceutical packaging plant in Dundalk, Ireland. Built with an…